Contineum Therapeutics, Inc.
CTNM
Positions held
Your positionsCTNM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $495.85M | Enterprise value | $265.87M | Trailing P/E | — | Forward P/E | -6.88 |
| PEG | — | Price / book | 2.07 | Beta | 0.86 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -28.0% | ROA | -19.2% | Debt / equity | 0.03 |
| Current ratio | 37.17 | Free cash flow | -$35.14M | Analyst recommendation | strong_buy | Mean target | $22.43 |
| 52w high | $17.79 | 52w low | $8.60 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$15.2M | -$14.5M | -$15.2M | -$12.8M | -$16.0M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$17.4M | -$16.9M | -$17.1M | -$14.9M | -$17.9M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $50.0M | $0.0M | — |
| Op margin | — | — | 32.2% | — | — |
| Net income | -$60.0M | -$42.3M | $22.7M | -$24.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$68.1M | -$50.9M | $16.1M | -$22.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
2026-09-24 · J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
2026-09-21 · RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk
2026-09-15 · Sector Update: Healthcare Stocks Ease Late Afternoon
2026-09-15 · Sector Update: Healthcare
2026-09-15 · FDA clears first generic radioligand drug; Sionna turns to layoffs
2026-09-15 · Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
2026-09-14 · CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
2026-09-14 · Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint
2026-09-14 · Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
2026-08-25 · Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Price (daily)
Full chart · RSI · MACD · patterns